-
39 listed companies disclosed their 2022 annual report performance forecasts, focusing on electronics, medicine and other fields
Time of Update: 2023-01-05
04% year-on-year Dongxing Medical announced on November 10 that it expects operating income from January to December 2022 to be 485 million yuan to 515 million yuan, an increase of 8.
-
Investment and financing in the field of medicine and biology are active, and enterprise innovation will usher in accelerated development
Time of Update: 2022-12-30
Prior to this, Guosen Pharmaceutical also announced the completion of a series B+ financing of nearly 100 million yuan, after the completion of this round of financing, the company will continue to focus on and deepen the clinical research of innovative drugs in cutting-edge pipelines, deepen business and technology, and continue to highlight the advantages in the field of cell and gene therapy (CGT).
-
The continuous involution of the domestic innovative drug industry will accelerate the forced pharmaceutical companies to move towards real innovation
Time of Update: 2022-10-20
com) The involution of domestic innovative drugs will accelerate the forced pharmaceutical companies to real innovation (Image source: Pharma.
com) In this regard, industry insiders believe that this is the result of the serious homogenization of domestic innovative drug research and development and the tendency of competition to be involutional.
-
Self-built M&A franchise alliance, pharmaceutical retail chain enterprises enter the "era of 10,000 stores
Time of Update: 2022-10-19
A few days ago, four listed chain pharmacy enterprises (hereinafter referred to as the four major chain pharmacies) including Da Shenlin Pharmaceutical Group Co. , Ltd. (hereinafter referred to as Da
-
The upgrading and transformation of traditional Chinese medicine enterprises has accelerated, and a large number of enterprises are focusing on the big health industry
Time of Update: 2022-10-12
On January 19 this year, Tailong Pharmaceutical also announced that the company intends to invest 50 million yuan to set up a wholly-owned subsidiary in Yunnan.
On January 19 this year, Tailong Pharmaceutical also announced that the company intends to invest 50 million yuan to set up a wholly-owned subsidiary in Yunnan.
-
Hemp seed stocks bottomed out, and the market is expected to continue to rise
Time of Update: 2022-09-06
Due to the low long-term price, the overall market attention of hemp seeds is limited, and the planting area of production areas has been shrinking in recent years .
-
In the first half of the year, a large number of multinational pharmaceutical companies such as Pfizer, Merck, and BMS maintained growth in performance
Time of Update: 2022-08-15
769 billion, a year-on-year increase of 70% According to Pfizer’s performance report for the first half of 2022, the company achieved total revenue of US$53.
494 billion, a year-on-year increase of 41% after deducting exchange rate effects Merck's 2022 first half financial report shows that the company achieved a total revenue of US$30.
-
To promote the high-quality development of the Chinese herbal medicine industry, how should pharmaceutical machine companies provide efficient "assistance
Time of Update: 2022-05-10
With the high-quality development of the Chinese herbal medicine industry, pharmaceutical machine companies will play an important role in strengthening the quality supervision of Chinese medicine products and ensuring the safety of public medication.
-
BASF releases "2021 BASF Automotive Original Paint Color Report
Time of Update: 2022-04-21
As BASF's color designers accurately predicted many years ago, the development of blue is booming, and red is rising like the rising sun, grabbing the market share of achromatic colors in many parts of the world .
-
In 2022, executives of pharmaceutical companies will change more frequently
Time of Update: 2022-02-19
On the 18th, Marc CROUTON, Chief Commercial Officer of the Fresenius Kabi Management Committee, and Ulf JASSON, Executive Vice President of the Asia Pacific Region, announced to the employees a personnel appointment, which will be executed by Fresenius Kabi China from February 1, 2022.
-
Touch the sun
Time of Update: 2021-12-26
This cup collects particles from the sun’s atmosphere that help scientists confirm that the spacecraft has indeed entered the corona .
The corona is the outermost layer of the sun's atmosphere, where a strong magnetic field confines the plasma and prevents the escape of the turbulent solar wind .
-
Eisai China won the 2020 Economic Contribution Award-Outstanding Contribution Award for Output Efficiency
Time of Update: 2021-10-22
Suzhou, October 8, 2021/PRNewswire/ - On September 28, Eisai China won the 2020 Economic Contribution in the 2021 Suzhou Municipal Government’s exchange activities with multinational companies and the awarding ceremony of the honorary title of Suzhou’s foreigners Award-Outstanding Contribution Award for Output Benefits, in recognition of the remarkable, iconic and leading contribution to Suzhou's economic development .
-
Another pharmaceutical company has entered the battle for over 15 billion yuan in the contrast agent market
Time of Update: 2021-09-30
In addition, in February of this year, Chengdu Better Pharmaceuticals also issued an announcement stating that its application for imitation listing of Category 4 iopromide injection was accepted, and it became the company's first contrast agent to apply for listing .
-
Analyze the research and development efficiency of the world's leading pharmaceutical companies in the past 20 years, and reveal the survival methods of pharmaceutical companies of different sizes
Time of Update: 2021-09-19
The latest issue of Drug Discovery Today published a paper on R&D efficiency of leading pharmaceutical companies — a 20-year analysis, which analyzed the R&D data of 14 global drug R&D le
-
China's "rare earth capital" pushes new policy to promote high-quality development of new rare earth materials
Time of Update: 2021-08-23
It is worth mentioning that, in order to better promote the high-quality development of new rare earth materials, the official also stated: All new rare earth materials and application enterprises that are registered, produced, actually sold in Baotou City and pay taxes according to law will be used for the working capital required for local projects.
